[Ultrasound scattering properties of Albunex microspheres]

In Japan, clinical and basic investigations of Albunex were started from 1989, and was firstly approved by the government as a commercially available contrast agent for the cardiovascular disorders. Although it has recently evacuated from the market, its acoustic properties proven by the many investigators were valuable for preparation of the second generation of contrast agents. Therefore, we summarized our data of the ultrasonic properties of Albunex both in vitro and experimental dog studies using RF signals. In conclusion, Albunex was a extremely sensitive blood flow tracer in evaluating intracardiac blood flow as well as intramyocardial perfusion.